The positive reputation of GLP-1 medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) continues to get bolstered. These drugs might even help keep some infectious diseases at bay. Two studies in recent weeks have found a link between GLP-1 use and a reduced risk of diseases like tuberculosis or infections serious enough to send people to the hospital. Though more research is needed to confirm this connection, GLP-1 drugs could very well offer a buffer against certain infections, particularly among more vulnerable groups like people with type 2 diabetes. “These findings suggest that beyond their established metabolic benefits, GLP-1RAs may confer additional advantages in lowering infection risk,” said the authors of one recent study, published late last month in the journal Nature Communications. Ozempic the germ buster? The authors of the Nature Communication study looked specifically at tuberculosis, or TB.…